Organization: Canadian Generic Pharmaceutical Association

Pharmaceutical R&D spending remains far below industry’s 10% commitment – PMPRB report

Another year of less-than-impressive R&D spending by the pharmaceutical industry has re-ignited the annual sparing match between industry and the organization that compiles the data. The Patented Medicines Prices Review Board (PMPRB) reports that companies belonging to Innovative Medicines Canada (IMC – formerly Rx&D) spent $770 million on R&D in 2016 or 4.9% of its $15.6 billion in sales – a ratio unchanged from 2015.

Generic drug report attacks brand-name industry

The Canadian Generic Pharmaceutical Association (CGPA) has released a report detailing what it calls the failure of brand-name drug companies to spend at least 10% of Canadian revenues on R&D. The report draws its information from the latest report of the Patented Medicines Prices Review Board. It shows that members of Canada’s Research-Based Pharmaceutical Companies…

Feds make changes to drug patent legislation

The federal government has introduced changes to the regulations governing patented medicines that is says will strengthen the economy “by restoring certainty, predictability and balance to Canada’s intellectual property framework for pharmaceuticals and biopharmaceuticals”. Effective October 5/06, the changes to Health Canada regulations extend the period of market exclusivity for new and innovative drugs from…